Home › Companies › INTRA-CELLULAR THERAPIES INC. › 2023-2024
Compiled from SEC Form N-PX filings and INTRA-CELLULAR THERAPIES INC.’s Form 8-K, filed 2024-06-18 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024 2024-2025
Explore INTRA-CELLULAR THERAPIES INC. in the interactive database Compare manager voting policies
These tallies are INTRA-CELLULAR THERAPIES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Joel S. Marcus | 54,287,176 | -- | -- | 38,126,412 | 3,812,995 | Majority: yes |
| Proposal 2: Approval of the Amended 2018 Plan, based on the following results: | 85,384,880 | 2,956,962 | 4,071,746 | -- | 3,812,995 | Majority: yes |
| Proposal 3: The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, based on the following results: | 88,688,988 | 3,237,807 | 4,299,788 | -- | 0 | Majority: yes |
| Proposal 4: On an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement was approved, based on the following votes: | 80,788,125 | 7,537,868 | 4,087,595 | -- | 3,812,995 | Majority: yes |
Source: INTRA-CELLULAR THERAPIES INC., Form 8-K, filed with the SEC on 2024-06-18 — read the filing on EDGAR.
Each item below shows how the 360 asset managers that disclosed a INTRA-CELLULAR THERAPIES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of INTRA-CELLULAR THERAPIES INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 10 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“Proposal 4: On an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement was approved, based on the following votes:”): 80,788,125 for, 7,537,868 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
The 354 asset managers below cast 92% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 22,815,687 | 0 | 0 | 0 | For |
| Vanguard | 10,769,314 | 0 | 0 | 0 | For |
| BlackRock | 7,964,151 | 19,868 | 0 | 0 | For |
| Invesco | 0 | 3,764,415 | 0 | 0 | Against |
| T. Rowe Price | 2,909,720 | 0 | 0 | 0 | For |
| WASATCH ADVISORS LP | 2,780,281 | 20,192 | 0 | 0 | For |
| JPMorgan | 2,318,576 | 0 | 0 | 0 | For |
| Charles Schwab | 2,222,280 | 0 | 0 | 0 | For |
| State Street | 2,178,619 | 28,307 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,204,635 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 2,135,726 | 0 | 0 | 0 | For |
| AllianceBernstein | 2,035,049 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 1,687,918 | 161 | 0 | 0 | For |
| Deep Track Capital, LP | 1,525,991 | 0 | 0 | 0 | For |
| Wellington | 1,423,209 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 1,372,114 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 1,291,551 | 0 | 0 | 0 | For |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,280,768 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 1,206,614 | 3,989 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 1,072,173 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,051,507 | 0 | 0 | 0 | For |
| Legg Mason | 1,006,717 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 990,389 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 924,590 | 0 | 0 | 0 | For |
| Northern Trust | 886,823 | 5,131 | 0 | 0 | For |
Showing the 25 largest of 354 asset managers. See all 354 in the interactive database.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“Proposal 3: The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, based on the following results:”): 88,688,988 for, 3,237,807 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
The 113 asset managers below cast 99.7% of the shares they voted on this item FOR (45,452,016 for, 102,680 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,493,088 | 0 | 0 | 0 | For |
| Fidelity | 10,186,077 | 0 | 0 | 0 | For |
| BlackRock | 4,545,940 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 2,135,726 | 0 | 0 | 0 | For |
| Invesco | 1,749,302 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,258,648 | 0 | 0 | 0 | For |
| Charles Schwab | 1,099,670 | 0 | 0 | 0 | For |
| Legg Mason | 1,006,717 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 990,389 | 0 | 0 | 0 | For |
| JPMorgan | 892,794 | 0 | 0 | 0 | For |
| TIAA | 825,243 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 694,609 | 0 | 0 | 0 | For |
| First Trust | 639,766 | 0 | 0 | 0 | For |
| AllianceBernstein | 570,007 | 0 | 0 | 0 | For |
| Lord Abbett | 463,762 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 419,947 | 0 | 0 | 0 | For |
| Principal | 407,944 | 0 | 0 | 0 | For |
| American Century | 390,414 | 0 | 0 | 0 | For |
| Brighthouse | 348,434 | 0 | 17,536 | 0 | For |
| Equitable | 358,720 | 0 | 0 | 0 | For |
| TimesSquare Capital Management, LLC | 343,606 | 0 | 0 | 0 | For |
| Hartford | 307,729 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 267,081 | 0 | 0 | 0 | For |
| Jackson National | 262,740 | 0 | 0 | 0 | For |
| AMG FUNDS | 253,068 | 0 | 0 | 0 | For |
Showing the 25 largest of 113 asset managers. See all 113 in the interactive database.
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“Proposal 2: Approval of the Amended 2018 Plan, based on the following results:”): 85,384,880 for, 2,956,962 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
The 112 asset managers below cast 98% of the shares they voted on this item FOR (44,788,869 for, 746,292 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,493,088 | 0 | 0 | 0 | For |
| Fidelity | 10,186,077 | 0 | 0 | 0 | For |
| BlackRock | 4,545,940 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 2,135,726 | 0 | 0 | 0 | For |
| Invesco | 1,749,302 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,258,648 | 0 | 0 | 0 | For |
| Charles Schwab | 1,099,670 | 0 | 0 | 0 | For |
| Legg Mason | 1,006,717 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 990,389 | 0 | 0 | 0 | For |
| JPMorgan | 892,794 | 0 | 0 | 0 | For |
| TIAA | 825,243 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 694,609 | 0 | 0 | 0 | For |
| First Trust | 639,766 | 0 | 0 | 0 | For |
| AllianceBernstein | 570,007 | 0 | 0 | 0 | For |
| Lord Abbett | 463,762 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 419,947 | 0 | 0 | 0 | For |
| Principal | 300,618 | 107,326 | 0 | 0 | For |
| American Century | 0 | 390,414 | 0 | 0 | Against |
| Brighthouse | 348,434 | 0 | 17,536 | 0 | For |
| Equitable | 358,720 | 0 | 0 | 0 | For |
| TimesSquare Capital Management, LLC | 343,606 | 0 | 0 | 0 | For |
| Hartford | 307,729 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 267,081 | 0 | 0 | 0 | For |
| Jackson National | 262,740 | 0 | 0 | 0 | For |
| AMG FUNDS | 253,068 | 0 | 0 | 0 | For |
Showing the 25 largest of 112 asset managers. See all 112 in the interactive database.
Combines 6 wordings of this item as funds reported it.
59% Majority: yes · of votes cast
INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“Elect Director: Joel S. Marcus”): 54,287,176 for, 38,126,412 withheld, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
The 111 asset managers below cast 100% of the shares they voted on this item FOR (22,702,213 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 958,550 | 0 | 9,534,538 | 0 | Abstain |
| Fidelity | 10,125,019 | 0 | 61,058 | 0 | For |
| BlackRock | 0 | 0 | 4,545,940 | 0 | Abstain |
| WASATCH FUNDS TRUST | 2,135,726 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 1,749,302 | 0 | Abstain |
| T. Rowe Price | 1,258,648 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 1,099,670 | 0 | Abstain |
| Legg Mason | 1,006,717 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 990,389 | 0 | Abstain |
| JPMorgan | 892,794 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 825,243 | 0 | Abstain |
| FRANKLIN STRATEGIC SERIES | 694,609 | 0 | 0 | 0 | For |
| First Trust | 639,766 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 570,007 | 0 | Abstain |
| Lord Abbett | 463,762 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 419,947 | 0 | Abstain |
| Principal | 179,428 | 0 | 228,516 | 0 | Abstain |
| American Century | 390,414 | 0 | 0 | 0 | For |
| Brighthouse | 113,542 | 0 | 252,428 | 0 | Abstain |
| Equitable | 1,200 | 0 | 357,520 | 0 | Abstain |
| TimesSquare Capital Management, LLC | 343,606 | 0 | 0 | 0 | For |
| Hartford | 307,729 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 267,081 | 0 | Abstain |
| Jackson National | 62,334 | 0 | 200,406 | 0 | Abstain |
| AMG FUNDS | 253,068 | 0 | 0 | 0 | For |
Showing the 25 largest of 111 asset managers. See all 111 in the interactive database.
97% Majority: yes · of votes cast
INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“Proposal 2: Approval of the Amended 2018 Plan, based on the following results:”): 85,384,880 for, 2,956,962 against, per its Form 8-K filed 2024-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
The 2 asset managers below cast 100% of the shares they voted on this item FOR (19,752 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Morningstar Funds Trust | 19,503 | 0 | 0 | 0 | For |
| Two Roads Shared Trust | 249 | 0 | 0 | 0 | For |
Ranked by the number of INTRA-CELLULAR THERAPIES INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting.
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | Fidelity | 22,815,687 |
| 2 | Vanguard | 10,769,314 |
| 3 | BlackRock | 7,984,019 |
| 4 | Invesco | 3,764,415 |
| 5 | T. Rowe Price | 2,909,720 |
| 6 | WASATCH ADVISORS LP | 2,800,473 |
| 7 | JPMorgan | 2,318,576 |
| 8 | Charles Schwab | 2,222,335 |
| 9 | State Street | 2,206,926 |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2,204,635 |
Shown as share counts, not percentages: no shares-outstanding figure has been matched to INTRA-CELLULAR THERAPIES INC. for the 2023-2024 season, so there is no denominator to divide by.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At INTRA-CELLULAR THERAPIES INC.'s shareholder meeting held 2024-06-14, in the 2023-2024 proxy season, 360 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,068 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve by an advisory vote the compensation of the Company's named executive officers, as… — FOR was 91% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: INTRA-CELLULAR THERAPIES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-18.
INTRA-CELLULAR THERAPIES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.